Protocol Ledger

NCT05877547 · Phase II · COMPLETED

A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

Interventional Phase II clinical trial protocol NCT05877547 sponsored by Merck & Co. in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-06-23 Enrollment: 381 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05877547
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)381 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05877547
Protocol FieldVerified Registry Value
NCT IdentifierNCT05877547
Consolidated Lead SponsorMerck & Co.
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment381 participants (ACTUAL)
Registered Start Date2023-06-23
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI